Q-omics provides the consensus-scored IRS1 profile across patient tissues and cancer cell-line models. IRS1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, IRS1 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, IRS1 RNA expression shows 19,313 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight BRCA, THCA, and KIRP as cancer lineages where IRS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IRS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IRS1 survival associations across molecular data types. IRS1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IRS1 RNA expression–survival associations across cancer types. High IRS1 expression shows unfavorable associations in LUSC and ACC, but favorable associations in BRCA, UCS, UCEC and THYM. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for IRS1 RNA expression.
This table summarizes IRS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for IRS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IRS1 shows lower tumor expression in THCA, KIRC and BRCA and higher tumor expression in HNSC, LUAD and COAD. The THCA box plot shows higher IRS1 RNA expression in normal versus tumor tissue (log2 FC = −2.670, t-test p < 0.001).
This table shows molecular features associated with IRS1 in patient tissues and cancer cell lines. In patient samples, IRS1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, IRS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
